Kiran Sonaje

Head, R&D

Advamedica

Mariann Micsinai-Balan

Vice President, Head of Data Science and Statistical Methodology

Bristol Myers Squibb

Fia Navntoft

Senior Clinical Project Manager

Mölnlycke Healthcare

Leo Mavely

Founder and Chief Executive Officer

AXIO Biosolutions

Leo Mavely is the CEO of Axio Biosolutions a medtech company focused on novel

biomaterials for advanced wound care and surgical solutions. Axiostat® its flagship product

which was developed to reduce the mortality due to traumatic bleeding from life threatening

injuries and is approved in over 45 countries and used by major armed forces globally. Their

more recent offering, Maxiocel is a 100% chitosan based advanced woundcare platform that

is CE marked and now used across Europe.

A bioengineer by qualification, Leo invented the core technology of Axio and is passionate

about building affordable healthcare products. Leo holds multiple patents and publications in

the field of novel biomaterials for medical tech applications.

Leo was featured in the list of 40 under 40 emerging business leaders by Fortune Magazine

consecutively in 2016, 2017, 2018 and 2019 and in the list of 35 under 35 entrepreneurs by

Entrepreneur magazine in 2020. He was the recipient of Silicon valley challenge 2014,

Anjani Mashelkar Inclusive Innovation Award 2013, CNBC Samsung Social Innovation

Award 2012 and was invited speaker at Indian Science congress 2010.

Axio has raised over $20mn in venture funding from Accel Partners, Ratan Tata’s UC-RNT

Fund, Omidyar network, Chiratate venture and TrueScale capital. Axio has its state of the art

R&D and manufacturing facility in India and is head quartered in Cambridge, USA.

Aaron Morales

Head of ESG - UK, Iberia & LatAm

S & P Global

Mallikarjun Choudhary

Executive Director

MSCI

Samir Kumar

GM & Managing Director

M12

Samir is a managing director at M12, leading investments globally where artificial intelligence or machine learning is a key point of leverage.

He also stewards the fund’s Vanguard Bets investment category—startups aiming for breakthroughs that will result in generational shifts in the technology landscape. Samir’s other investment focuses include quantum computing, robotics, autonomous systems, transportation and silicon—especially for AI. Samir manages a team developing theses for new technology areas and oversees the fund’s technical and scientific advisory board.

Prior to joining M12, Samir was a senior director of business development and product management in Qualcomm’s corporate R&D division. There, he led early-stage product validation, partnerships, acquisitions, and strategy for embedded machine learning, computer vision and heterogeneous computing. Samir started his career at Microsoft, where he spent several years leading product management and product planning efforts for enterprise mobility before joining Palm and Samsung.

Samir is a regular conference speaker on his investment focus areas. He has served on or moderated panels of VCs and subject matter experts at LDV Vision Summit, tinyML Summit, and Cybersec&AI Connected.